PSCR — Proto Script Pharmaceutical Share Price
Last trade - 00:00- $0.01m
- $0.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1298.51% | ||
Financial Summary
| Year End 31st May | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Proto-Script Pharmaceuticals, Corp., formerly Yanex Group, Inc. is a development-stage company. The Company is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. The Company has various contracts with state and governmental insurance providers, among others. These contracts provide the Company the right to sell and repair DME. The Company's health care insurance contracts allow it the ability to service patients nationally. The Company intends to expand its market through additional contracts and open several repair facilities throughout the continental United States. The Company currently has repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California. As of June 30, 2016, the Company had not generated any revenues.
Directors
- Last Annual
- May 31st, 2016
- Last Interim
- September 30th, 2017
- Incorporated
- November 18th, 2010
- Public Since
- November 25th, 2011
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 49,139,998
- Address
- 9830 6Th Street, Suite 103, RANCHO CUCAMONGA, 91730
- Web
- Phone
- +1 7077141088
- Auditors
- KLJ & Associates LLP
Upcoming Events for PSCR
Similar to PSCR
1PM Industries
Pink Sheets on Nasdaq
3Dshopping.Com
Pink Sheets on Nasdaq
3 Sixty Risk Solutions
Pink Sheets on Nasdaq
ACS Global
Pink Sheets on Nasdaq
Adecco AG
Pink Sheets on Nasdaq
FAQ
As of Today at 22:47 UTC, shares in Proto Script Pharmaceutical are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Proto Script Pharmaceutical last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Proto Script Pharmaceutical share price has underperformed the S&P500 Index by -16.07% over the past year.
There is no consensus recommendation for this security.
Proto Script Pharmaceutical does not currently pay a dividend.
Proto Script Pharmaceutical does not currently pay a dividend.
Proto Script Pharmaceutical does not currently pay a dividend.
To buy shares in Proto Script Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Proto Script Pharmaceutical had a market capitalisation of $0.01m.
Here are the trading details for Proto Script Pharmaceutical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PSCR
Based on an overall assessment of its quality, value and momentum Proto Script Pharmaceutical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proto Script Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -96.38%.
As of the last closing price of $0.00, shares in Proto Script Pharmaceutical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Proto Script Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Proto Script Pharmaceutical's management team is headed by:
- Michelle Rico - PRE